ERC Society for Endocrinology Archive
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Endocrine-Related Cancer 6 (3) 333-347    DOI: 10.1677/erc.0.0060333
Copyright © 1999 by the Society for Endocrinology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (60)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boyce, B.
Right arrow Articles by Guise, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boyce, B.
Right arrow Articles by Guise, T.
Endocrine Related Cancer, Vol 6, Issue 3, 333-347
Copyright © 1999 by Society for Endocrinology


Articles

Factors regulating the growth of metastatic cancer in bone

BF Boyce, T Yoneda, and TA Guise


Metastatic tumor cells can interfere directly with the function of bone cells involved in normal bone remodeling or indirectly by influencing the behavior of hematopoietic, stromal and other cells in bone marrow that interact with bone cells. Recent studies of metastatic cancer have revealed that tumor cells interact closely with vascular endothelial cells, basement membrane and bone marrow stromal cells through cell surface proteins or by releasing factors which affect the function of these cells. Bidirectional interaction between marrow cells and tumor cells can give the latter a selective advantage for growth in bone which can lead to the destruction of or to increased production of bone matrix. Understanding of the mechanisms involved in tumor metastasis and growth in bone has increased in recent years, and in this review we shall describe current knowledge of these mechanisms and of the predilection of certain types of cancers to metastasize to bone, their growth in the bone microenvironment and interactions between them and bone cells. Because metastatic breast cancer has been studied more than any other, we shall focus on it as a representative example, although the general principles apply to other types of cancer and to myeloma.


This article has been cited by other articles:


Home page
Vet PatholHome page
A. A. El-Mabhouh, P. N. Nation, A. Kaddoura, and J. R. Mercer
Unexpected Preferential Brain Metastases with a Human Breast Tumor Cell Line MDA-MB-231 in BALB/c Nude Mice
Vet. Pathol., November 1, 2008; 45(6): 941 - 944.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. D. Moore, T. Isayeva, G. P. Siegal, and S. Ponnazhagan
Silencing of Transforming Growth Factor-{beta}1 In situ by RNA Interference for Breast Cancer: Implications for Proliferation and Migration In vitro and Metastasis In vivo
Clin. Cancer Res., August 1, 2008; 14(15): 4961 - 4970.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. E. Talmadge
Follistatin as an Inhibitor of Experimental Metastasis
Clin. Cancer Res., February 1, 2008; 14(3): 624 - 626.
[Full Text] [PDF]


Home page
FASEB J.Home page
A. K. Sasser, N. J. Sullivan, A. W. Studebaker, L. F. Hendey, A. E. Axel, and B. M. Hall
Interleukin-6 is a potent growth factor for ER-{alpha}-positive human breast cancer
FASEB J, November 1, 2007; 21(13): 3763 - 3770.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
J. C. O'Connor, M. C. Farach-Carson, C. J. Schneider, and D. D. Carson
Coculture with Prostate Cancer Cells Alters Endoglin Expression and Attenuates Transforming Growth Factor-{beta} Signaling in Reactive Bone Marrow Stromal Cells
Mol. Cancer Res., June 1, 2007; 5(6): 585 - 603.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. G. Marguiles, V. S. Klimberg, S. Bhattacharrya, D. Gaddy, and L. J. Suva
Genomics and Proteomics of Bone Cancer.
Clin. Cancer Res., October 15, 2006; 12(20): 6217s - 6221s.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. M. van Golen, T. S. Schwab, B. Kim, M. E. Soules, S. Su Oh, K. Fung, K. L. van Golen, and E. L. Feldman
Insulin-Like Growth Factor-I Receptor Expression Regulates Neuroblastoma Metastasis to Bone.
Cancer Res., July 1, 2006; 66(13): 6570 - 6578.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Kitagawa, J. Dai, J. Zhang, J. M. Keller, J. Nor, Z. Yao, and E. T. Keller
Vascular Endothelial Growth Factor Contributes to Prostate Cancer-Mediated Osteoblastic Activity
Cancer Res., December 1, 2005; 65(23): 10921 - 10929.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Kelly, L. J. Suva, Y. Huang, V. MacLeod, H.-Q. Miao, R. C. Walker, and R. D. Sanderson
Expression of Heparanase by Primary Breast Tumors Promotes Bone Resorption in the Absence of Detectable Bone Metastases
Cancer Res., July 1, 2005; 65(13): 5778 - 5784.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. T. Price, J. M.W. Quinn, N. A. Sims, J. Vieusseux, K. Waldeck, S. E. Docherty, D. Myers, A. Nakamura, M. C. Waltham, M. T. Gillespie, et al.
The Heat Shock Protein 90 Inhibitor, 17-Allylamino-17-demethoxygeldanamycin, Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Human Breast Cancer Cell Line
Cancer Res., June 1, 2005; 65(11): 4929 - 4938.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S.-J. Kim, H. Uehara, S. Yazici, J. He, R. R. Langley, P. Mathew, D. Fan, and I. J. Fidler
Modulation of Bone Microenvironment with Zoledronate Enhances the Therapeutic Effects of STI571 and Paclitaxel against Experimental Bone Metastasis of Human Prostate Cancer
Cancer Res., May 1, 2005; 65(9): 3707 - 3715.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Korah, M. Boots, and R. Wieder
Integrin {alpha}5{beta}1 Promotes Survival of Growth-Arrested Breast Cancer Cells: An in Vitro Paradigm for Breast Cancer Dormancy in Bone Marrow
Cancer Res., July 1, 2004; 64(13): 4514 - 4522.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Dai, Y. Kitagawa, J. Zhang, Z. Yao, A. Mizokami, S. Cheng, J. Nor, L. K. McCauley, R. S. Taichman, and E. T. Keller
Vascular Endothelial Growth Factor Contributes to the Prostate Cancer-Induced Osteoblast Differentiation Mediated by Bone Morphogenetic Protein
Cancer Res., February 1, 2004; 64(3): 994 - 999.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Alvarez, M. Westmore, R. J. S. Galvin, C. L. Clapp, E. L. Considine, S. J. Smith, K. Keyes, P. W. Iversen, D. M. Delafuente, S. Sulaimon, et al.
Properties of Bisphosphonates in the 13762 Rat Mammary Carcinoma Model of Tumor-Induced Bone Resorption
Clin. Cancer Res., November 15, 2003; 9(15): 5705 - 5713.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Fizazi, J. Yang, S. Peleg, C. R. Sikes, E. L. Kreimann, D. Daliani, M. Olive, K. A. Raymond, T. J. Janus, C. J. Logothetis, et al.
Prostate Cancer Cells-Osteoblast Interaction Shifts Expression of Growth/Survival-related Genes in Prostate Cancer and Reduces Expression of Osteoprotegerin in Osteoblasts
Clin. Cancer Res., July 1, 2003; 9(7): 2587 - 2597.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pathol.Home page
G Ellison, T Klinowska, R F R Westwood, E Docter, T French, and J C Fox
Further evidence to support the melanocytic origin of MDA-MB-435
Mol. Pathol., October 1, 2002; 55(5): 294 - 299.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. S. Bendre, D. Gaddy-Kurten, T. Mon-Foote, N. S. Akel, R. A. Skinner, R. W. Nicholas, and L. J. Suva
Expression of Interleukin 8 and not Parathyroid Hormone-related Protein by Human Breast Cancer Cells Correlates with Bone Metastasis in Vivo
Cancer Res., October 1, 2002; 62(19): 5571 - 5579.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
B. A. Watkins, Y. Li, H. E. Lippman, and M. F. Seifert
Omega-3 Polyunsaturated Fatty Acids and Skeletal Health
Experimental Biology and Medicine, June 1, 2001; 226(6): 485 - 497.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. R. Berenson, R. A. Vescio, L. S. Rosen, J. M. VonTeichert, M. Woo, R. Swift, A. Savage, E. Givant, M. Hupkes, H. Harvey, et al.
A Phase I Dose-ranging Trial of Monthly Infusions of Zoledronic Acid for the Treatment of Osteolytic Bone Metastases
Clin. Cancer Res., March 1, 2001; 7(3): 478 - 485.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the Society for Endocrinology.